Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin Commercialization

  • Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) entered into a loan facility with Oxford Finance LLC for $150 million to support commercial preparations and the potential launch of sotagliflozin in heart failure.
  • The loan facility consists of four tranches, each maturing in March 2027.
  • An initial $25 million tranche was funded at closing. The second $25 million tranche is available before August 31, contingent upon the acceptance of filing by the FDA of Lexicon's planned resubmission of sotagliflozin for heart failure.
  • Related: Lexicon Pharma Pulls Sotagliflozin US Application Due To Technical Issue, Shares Fall.
  • The third $50 million tranche is available before June 30, 2023, contingent upon U.S. approval of sotagliflozin for heart failure. 
  • The final $50 million tranche is available before the expiration of a three or four-year interest-only payment period.
  • In connection with the initiation of the facility and first tranche funding, Lexicon granted Oxford a warrant to purchase 420,673 shares of Lexicon's common stock at an exercise price of $2.08 per share, exercisable through March 2027. 
  • Price Action: LXRX shares are up 3.64% at $2.28 on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.